• SPX
  • $5,544.59
  • -0.78 %
  • -$43.68
  • DJI
  • $40,665.02
  • -1.29 %
  • -$533.08
  • N225
  • $40,044.58
  • -0.2 %
  • -$81.55
  • FTSE
  • $8,204.89
  • 0.21 %
  • $17.43
  • IXIC
  • $17,871.22
  • -0.7 %
  • -$125.70

Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News & Analysis

Currency in USD Disclaimer

$42.77

-$1.12

(-2.55%)

Day's range
$41.99
$44.6
52 wk range
$31.52
$54.56
50-day range
$37.02
$46.2
  • Country: US
  • ISIN: US90400D1081
RARE Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.51
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (RARE)
  • Company Ultragenyx Pharmaceutical Inc.
  • Price $42.77
  • Changes Percentage (-2.55%)
  • Change -$1.12
  • Day Low $41.99
  • Day High $44.60
  • Year High $54.56

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 08/01/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $113.00
  • High Stock Price Target $150.00
  • Low Stock Price Target $67.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$7.95
  • Trailing P/E Ratio -5.21
  • Forward P/E Ratio -5.21
  • P/E Growth -5.21
  • Net Income $-606,639,000

Income Statement

Quarterly

Annual

Latest news of RARE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In


or

Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.